Effects of a combination of exemestane and paclitaxel on human tumor cells in vitro

Danqing Chen,Wolfgang Hackl,Olaf Ortmann,Oliver Treeck

DOI: https://doi.org/10.1097/00001813-200401000-00009

2004-01-01

Abstract:Exemestane, a non-steroidal aromatase inhibitor that shuts down estrogen synthesis, and paclitaxel, an antineoplastic drug, inhibiting microtubule formation and interfering with the cells potential to proliferate, are well established treatments for metastatic breast cancer. Given that exemestane is a treatment for hormone-sensitive tumors in postmenopausal women with more favorable prognosis, while paclitaxel is normally used for women suffering from hormone-insensitive breast cancers with less favorable prognoses, there is currently no experience with the combination of the two drugs. In order to find out to what extent exemestane and paclitaxel add to each other's effects when given concomitantly, the effect of the two drugs alone and in combination on the growth of various gynecological tumor cell lines was assessed. Tumor cell growth was measured according to the cell titer cell proliferation technique, also referred to as the MTS assay, by measurement of relative cell numbers. In gynecological cancer cells expressing aromatase, the effect of a treatment with paclitaxel (10 nM) on cell growth was enhanced by co-treatment with exemestane. This additive effect was independent of ERalpha expression, but dependent on the presence of androstenedione. It was observed in HEC-1A and Ishikawa endometrial adenocarcinoma cells as well as in SK-OV-3 ovarian cancer and in MDA-MB-231 breast cancer cells. Our findings suggest that a combination of paclitaxel with exemestane might be beneficial for the treatment of aromatase-positive gynecological cancer, because it may allow us to reduce the paclitaxel dosage and therefore the toxicity of the treatment.

oncology,pharmacology & pharmacy

What problem does this paper attempt to address?

The main problem that this paper attempts to solve is to explore the effect of the combined use of the non - steroidal aromatase inhibitor exemestane and the anti - tumor drug paclitaxel on the growth of human gynecological tumor cell lines. Specifically, researchers hope to understand whether these two drugs can enhance each other's effects when used simultaneously, especially whether this combination therapy has a better inhibitory effect on gynecological tumor cells expressing aromatase, and whether this combination can reduce the dose of paclitaxel and thus reduce its toxicity.

The research background includes:
- Exemestane is a non - steroidal aromatase inhibitor. It treats hormone - sensitive breast cancer by shutting down estrogen synthesis and is mainly applicable to post - menopausal women.
- Paclitaxel is an anti - tumor drug. It interferes with the cell proliferation ability by inhibiting microtubule formation and is usually used to treat hormone - insensitive breast cancer, which has a poor prognosis.
- There is currently no experience in the combined use of these two drugs.

The research methods include:
- Measuring the relative cell number by cell proliferation technology (MTS assay) to evaluate the growth of different gynecological tumor cell lines after using exemestane and paclitaxel alone or in combination.
- Evaluating the cell growth inhibition effect under different conditions (such as media with or without androstenedione).

The research results show that in gynecological tumor cells expressing aromatase, the combined use of exemestane and paclitaxel significantly enhances the inhibitory effect on cell growth. This enhanced effect is independent of the expression of estrogen receptor α (ERα), but depends on the presence of androstenedione. These findings suggest that the combined use of exemestane and paclitaxel may be beneficial for the treatment of gynecological tumors expressing aromatase, because it may allow the reduction of the dose of paclitaxel, thereby reducing the toxicity of the treatment.